Mario Lacouture, MD
Enriched profileChief, Dermatology Division, NYU Langone Hospital–Long Island; Professor, Department of Medicine, NYU Grossman Long Island School of Medicine; Medical Director, Symptom Management Program, Perlmutter Cancer Center–Long Island · NYU Langone Health
Mario Lacouture is Chief, Dermatology Division, NYU Langone Hospital–Long Island; Professor, Department of Medicine, NYU Grossman Long Island School of Medicine; Medical Director, Symptom Management Program, Perlmutter Cancer Center–Long Island at NYU Langone Health. OpenAlex indexes 703 publications with 28,964 citations (h-index 88); ClinicalTrials.gov lists 11 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 1% of Dermatology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Mario Lacouture, MD, is Chief, Dermatology Division, NYU Langone Hospital–Long Island at NYU Langone Health. The public record shows 703 publications with 28,964 citations (h-index 88), centered on Colorectal Cancer Treatments and Studies, Chemotherapy-related skin toxicity, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 14 companies.
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Colorectal Cancer Treatments and Studies
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 14 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 19 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 283.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients
Sponsor: OnQuality Pharmaceuticals (USA) LLC
- Study Determining Safety and Efficacy of Avena Sativa (Oat) Skincare Products for Treating Skin Dryness and Itching in Cancer Patients
Sponsor: Johnson & Johnson Consumer Inc. (J&JCI)
Industry payments
Updated 14 Oct 2026
14 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Cipher Pharmaceuticals US LLCProgram year20251 payment
- GENZYME CORPORATIONProgram year20241 payment
- Daiichi Sankyo Inc.Program year20241 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
43.9%Corticosteroid17.1%Triamcinolone Acetonide71%Fluocinolone Acetonide29%Part D≥187 patientsalpha-Hydroxy Acid10.1%Ammonium Lactate100%Part D≥145 patients+ 5 more classes in this area
Sensory organs
12.8%Corticosteroid9.8%Clobetasol Propionate77%Hydrocortisone16%Alclometasone Dipropionate8%Part D≥116 patientsAminoglycoside Antibacterial1.9%Gentamicin Sulfate100%Part D≥33 patients+ 2 more classes in this area
Anti-infectives
12.4%Azole Antifungal5.9%Ketoconazole100%Part D≥84 patientsTetracycline-class Drug2%Doxycycline Hyclate56%Minocycline Hcl44%Part D≥21 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 14 Oct 2026
137 congress contributions (2007–2026) across AACR, ASCO, ASH, ASTRO, ESMO per OpenAlex. The most recent:
- Oncologic outcomes following biologic therapy for immune-related cutaneous adverse events.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Benralizumab relieves Eosinophil-Related Cutaneous Adverse Events from Cancer Therapy: A Nonrandomized Phase 2 Trial.
Clinical cancer research
Article2026 - Management of human epidermal growth factor receptor inhibitors-related acneiform rash: A position paper based on the first Europe/USA Delphi consensus process.
Journal of the European Academy of Dermatology and Venereology
Article2025 - Predictors of immediate and delayed cutaneous hypersensitivity reactions to paclitaxel.
Archives of dermatological research
Article2024 - Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways.
Clinical cancer research
Article2024
Most-cited works
by citation count (OpenAlex)- 01
- 02Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies1,466 citations2015
- 03
- 04Mechanisms of cutaneous toxicities to EGFR inhibitors779 citations2006
- 05
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- LinkedIn
linkedin.com/in/mario-lacouture-m-d-26811819
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - LinkedIn
linkedin.com/in/mario-lacouture-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Mario-Lacouture
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - Doximity
doximity.com/pub/mario-lacouture-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗ - Doximity
doximity.com/pub/mario-lacouture-md-11e5319f
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗ - Instagram
instagram.com/lacouturemd
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com ↗
Mentions by others
where others cite or feature them- YouTube
mskcc.org/podcasts/cancer-straight-talk/how-to-manage-side-effects-during-cancer-treatment-fatigue-hair-loss
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
Editorial & leadership roles
journal and society appointments- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodermatologysociety.org ↗
- Editor
textbook "Dermatologic Principles and Practice in Oncology"
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗ - Member
Guidelines Advisory Committee, American Society of Clinical Oncology (ASCO)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗ - Editorial Board
Cancer.Net
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗ - Past board member and former chair
Oncodermatology Study Group, Multinational Association of Supportive Care in Cancer (MASCC)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →biospace.com ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →orcid.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →orcid.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →orcid.org ↗
Media & interviews
press, podcasts and appearances- "Hair Loss? Rashes? Dr. Mario Lacouture Specializes in Easing Cancer-Treatment Side Effects"
NYU Langone News feature
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →jddonline.com ↗
- "Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture"
ILCN.org (International Lung Cancer News/WCLC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ilcn.org ↗ - "Dr Mario E. Lacouture on Maintaining Quality of Life While Treating Melanomas"
AJMC video/interview feature
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ajmc.com ↗ - "Physician Spotlight: Mario E. Lacouture, MD"
Practical Dermatology profile
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →practicaldermatology.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Gareth Morgan, MD
NYU Langone Health
Nathan Levin, MD
NYU Langone Health
Ira Jacobson, MD
NYU Langone Health
Michael Zelefsky, MD
NYU Langone Health
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH